Teleflex (TFX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.76
- Estimate
- $1.28
- Surprise
- +37.4%
- Revenue (period 2026-06-30)
- $570.3M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
Teleflex (TFX) beat the $1.28 estimate with adjusted EPS of $1.76 — a large 37.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.4/10) to Hold at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TFX Hold at 6.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +37.4% surprise compares with a +3.0% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Thin upside margin: 9.1%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5)
- Leverage penalty (D/E 1.0): -0.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $123.44
- Price target
- $134.61
- Stop
- $116.56
- Upside to target
- +9.1%
- Reward-to-risk
- 1.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
TFX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $5.27B
- P/E (fwd)
- 11.4
- 52-week range
- $100.18–$145.00
- Off 52-week high
- 14.9%
- RSI (14)
- 59
- Volume vs avg
- 0.59×
- Score today
- 6.2/10